2026 Dyslipidemia Guideline Expands Statin Eligibility to 21.5 Million More US Adults

The 2026 American Heart Association/American College of Cardiology dyslipidemia guideline substantially expands the US population eligible for primary prevention statin therapy, with much of the increase occurring among younger and lower-risk adults, according to a new analysis published in JAMA.¹

Using National Health and Nutrition Examination Survey data from 2017 to 2023, investigators estimated that 87.5 million nonpregnant US adults aged 30 to 79 years without known atherosclerotic cardiovascular disease (ASCVD) are eligible for primary prevention statin therapy under the 2026 guideline. That represents 56.6% of the target population.¹

The analysis also estimated that 21.5 million adults, or 13.9% of the target population, are newly statin eligible under the 2026 guideline compared with the 2018 cholesterol guideline. Newly eligible adults were largely younger and had lower estimated ASCVD risk than adults previously recommended statin therapy. Mean estimated 10-year ASCVD risk was 3.1% among newly eligible individuals compared with 6.1% among those eligible under both the 2018 and 2026 guidelines.¹

What changed in the 2026 dyslipidemia guideline?

The 2026 guideline includes several changes with potential implications for primary prevention statin decisions. It expands the age range for ASCVD risk estimation from adults aged 40 to 75 years to those aged 30 to 79 years. It also adds stage 3 or higher chronic kidney disease and HIV infection as indications for statin eligibility independent of ASCVD risk estimation, joining LDL-C of 190 mg/dL or greater and diabetes.²

The guideline also lowers 10-year ASCVD risk thresholds, defining low risk as less than 3%, borderline risk as 3% to less than 5%, intermediate risk as 5% to less than 10%, and high risk as 10% or greater. It replaces the pooled cohort equations with the PREVENT-ASCVD equations for 10-year risk estimation and adds use of 30-year ASCVD risk among adults aged 30 to 59 years.²

How many adults are eligible for statins?

Among the estimated 154.5 million US adults aged 30 to 79 years without known ASCVD, 17.8% reported currently taking statins, 8.6% met criteria for statin eligibility independent of ASCVD risk estimation, and 5.5% had untreated LDL-C levels below 70 mg/dL, for whom statin therapy is not recommended regardless of estimated ASCVD risk.¹

The remaining 68.0% met guideline criteria for ASCVD risk estimation to guide statin decisions. Within this group, an estimated 3.2 million adults were classified as high risk, 11.4 million as intermediate risk, 12.9 million as borderline risk, and 77.6 million as low risk. Among low-risk adults, 5.4 million met statin eligibility criteria because of LDL-C levels of 160 to 189 mg/dL, and 13.7 million met criteria because of 30-year ASCVD risk of 10% or higher.¹

Eligibility varied sharply by age. More than 93% of adults aged 70 to 79 years and 85% of adults aged 60 to 69 years were eligible for primary prevention statin therapy, compared with 11% of adults aged 30 to 39 years and 39.9% of adults aged 40 to 49 years.¹

What are the clinical implications?

For primary care clinicians, the findings suggest that the 2026 guideline may substantially increase the number of patients who warrant a statin discussion, particularly younger adults with low 10-year but elevated 30-year ASCVD risk and adults with moderately elevated LDL-C.¹

The authors noted that the expanded eligibility does not automatically mean every newly eligible patient should start a statin. The guideline emphasizes lifestyle counseling and shared decision-making, particularly for lower-risk patients. The study authors also highlighted the need to better understand patient preferences, cost-effectiveness, and the balance of long-term benefit and potential harms in younger, lower-risk populations.¹

The analysis has limitations. Estimates were based on 4366 NHANES participants extrapolated to the US adult population. Medication use and ASCVD history were self-reported, and NHANES did not include HIV status or peripheral artery disease, both of which are addressed in the 2026 guideline. The study also focused on statin eligibility and did not estimate changes in ASCVD event reduction, statin-related adverse effects, statin intensity, or achievement of lipid-lowering goals.¹

Investigators concluded that the 2026 dyslipidemia guideline expands primary prevention statin eligibility by an estimated 21 million US adults, with most newly eligible individuals having less than 3% estimated 10-year ASCVD risk.¹

Reference

1. Anderson TS, Wilson LM, Sussman JB. Implications of the 2026 dyslipidemia guideline for primary prevention statin therapy. JAMA. Published online July 20, 2026. doi:10.1001/jama.2026.11246
2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87:2624-2757. doi:10.1016/j.jacc.2025.11.016